title: Dopamine D(3) receptor antagonists. 1. Synthesis and structure-activity relationships of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans.
abstract: 5,6-Dimethoxy-2-(N-dipropyl)-aminoindan (3, PNU-99194A) was found to be a selective dopamine D(3) receptor antagonist with potential antipsychotic properties in animal models. To investigate the effects of nitrogen substitution on structure-activity relationships, a series of 5,6-dimethoxy-N-alkyl- and N-alkylaryl-substituted 2-aminoindans were synthesized and evaluated in vitro for binding affinity and metabolic stability. The results indicate that substitution at the amine nitrogen of the 2-aminoindans is fairly limited to the di-N-propyl group in order to achieve selective D(3) antagonists. Thus, combinations of various alkyl groups were generally inactive at the D(3) receptor. Although substitution with an N-alkylaryl or N-alkylheteroaryl group yields compounds with potent D(3) binding affinity, the D(2) affinity is also enhanced, resulting in a less than 4-fold preference for the D(3) receptor site, and no improvements in metabolic stability were noted. A large-scale synthesis of the D(3) antagonist 3 has been developed that has proven to be reproducible with few purification steps. The improvements include the use of 3,4-dimethoxybenzaldehyde as a low-cost starting material to provide the desired 5,6-dimethoxy-1-indanone 5c in good overall yield (65%) and the formation of a soluble silyl oxime 17 that was reduced efficiently with BH(3).Me(2)S. The resulting amino alcohol was alkylated and then deoxygenated using a Lewis acid and Et(3)SiH to give the desired product 3 in good overall yield of ( approximately 65%) from the indanone 5c.
authors.affiliation: Structural, Analytical and Medicinal Chemistry, Pharmacia, 7255-209-129.2, 301 Henrietta Street, Kalamazoo, Michigan 49007-4940, USA. sue.haadsma-svensson@pharmacia.com
authors.forename: S R
authors.initials: SR
authors.lastname: Haadsma-Svensson
authors.forename: K A
authors.initials: KA
authors.lastname: Cleek
authors.forename: D M
authors.initials: DM
authors.lastname: Dinh
authors.forename: J N
authors.initials: JN
authors.lastname: Duncan
authors.forename: C L
authors.initials: CL
authors.lastname: Haber
authors.forename: R M
authors.initials: RM
authors.lastname: Huff
authors.forename: M E
authors.initials: ME
authors.lastname: Lajiness
authors.forename: N F
authors.initials: NF
authors.lastname: Nichols
authors.forename: M W
authors.initials: MW
authors.lastname: Smith
authors.forename: K A
authors.initials: KA
authors.lastname: Svensson
authors.forename: M J
authors.initials: MJ
authors.lastname: Zaya
authors.forename: A
authors.initials: A
authors.lastname: Carlsson
authors.forename: C H
authors.initials: CH
authors.lastname: Lin
mesh_terms: D000818:Animals; D001667:Binding, Competitive; D016466:CHO Cells; D002455:Cell Division / Q000187:drug effects; D006224:Cricetinae; D018492:Dopamine Antagonists / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D022781:Hepatocytes / Q000187:drug effects / Q000378:metabolism; D066298:In Vitro Techniques; D007189:Indans / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology; D008297:Male; D009043:Motor Activity / Q000187:drug effects; D011869:Radioligand Assay; D051381:Rats; D017207:Rats, Sprague-Dawley; D017448:Receptors, Dopamine D2 / Q000187:drug effects*; D050637:Receptors, Dopamine D3; D013329:Structure-Activity Relationship
chemical_list: D018492:Dopamine Antagonists; C493595:Drd3 protein, rat; D007189:Indans; D017448:Receptors, Dopamine D2; D050637:Receptors, Dopamine D3; C086335:(5,6-dimethoxyindan-2-yl)dipropylamine